Table 3.
Most common TRAEs
| Treatment-related adverse events, n (%) | All patients (N = 28) | |
|---|---|---|
| Grade 1–2 | Grade 3 | |
| Any TRAE | 17 (60.7) | 11 (39.3) |
| Lymphocyte count decreased | 12 (42.9) | 2 (7.1) |
| White blood cell count decreased | 12 (42.9) | 0 |
| Pyrexia | 12 (42.9) | 0 |
| Hypothyroidism | 9 (32.1) | 0 |
| Blood thyroid-stimulating hormone increased | 7 (25.0) | 0 |
| Blood glucose increased | 7 (25.0) | 0 |
| Upper respiratory tract infection | 6 (21.4) | 1 (3.6) |
| Hemoglobin decreased | 6 (21.4) | 0 |
| Platelet count decreased | 5 (17.9) | 1 (3.6) |
| Globulin increased | 5 (17.9) | 0 |
| Blood alkaline phosphatase increased | 5 (17.9) | 0 |
| Nasosinusitis | 5 (17.9) | 0 |
| Urinary tract infection | 5 (17.9) | 0 |
Listed are any TRAEs occurring in ≥15% patients
TRAE treatment-related adverse event